调节肠-肝轴以及粪便微生物群在肝硬化中的关键作用。
Modulating the gut-liver axis and the pivotal role of the faecal microbiome in cirrhosis.
作者信息
Woodhouse Charlotte, Singanayagam Arjuna, Patel Vishal C
机构信息
King's College London, London, UK and King's College Hospital NHS Foundation Trust, London, UK.
St George's University Hospitals NHS Foundation Trust, London, UK and senior clinical lecturer, St George's University of London, London, UK.
出版信息
Clin Med (Lond). 2020 Sep;20(5):493-500. doi: 10.7861/clinmed.2020-0676.
Abstract
Cirrhosis is associated with intestinal dysbiosis, with specific alterations in the gut microbiota linked to particular aetiologies and manifestations of the disease. We review the role of the gut microbiome and the importance of the intestinal barrier in cirrhosis, provide an overview of the terminology and techniques relevant to this emerging area, and discuss the latest developments in therapies targeting the gut-liver axis.
摘要
肝硬化与肠道菌群失调有关，肠道微生物群的特定改变与该疾病的特定病因和表现相关。我们回顾了肠道微生物组的作用以及肠道屏障在肝硬化中的重要性，概述了与这一新兴领域相关的术语和技术，并讨论了针对肠-肝轴的治疗方法的最新进展。
相似文献
1
Modulating the gut-liver axis and the pivotal role of the faecal microbiome in cirrhosis.
Clin Med (Lond). 2020 Sep;20(5):493-500. doi: 10.7861/clinmed.2020-0676.
2
Microbiota, cirrhosis, and the emerging oral-gut-liver axis.
JCI Insight. 2017 Oct 5;2(19):94416. doi: 10.1172/jci.insight.94416.
3
The gut-liver axis in liver disease: Pathophysiological basis for therapy.
J Hepatol. 2020 Mar;72(3):558-577. doi: 10.1016/j.jhep.2019.10.003. Epub 2019 Oct 14.
4
Promises of microbiome-based therapies.
J Hepatol. 2022 Jun;76(6):1379-1391. doi: 10.1016/j.jhep.2021.12.003.
5
The gut microbiota-bile acid axis in cholestatic liver disease.
Mol Med. 2024 Jul 19;30(1):104. doi: 10.1186/s10020-024-00830-x.
6
Role of gut microbiota in the pathogenesis and therapeutics of minimal hepatic encephalopathy the gut-liver-brain axis.
World J Gastroenterol. 2023 Jan 7;29(1):144-156. doi: 10.3748/wjg.v29.i1.144.
7
The gut-liver axis in immune remodeling of hepatic cirrhosis.
Front Immunol. 2022 Aug 8;13:946628. doi: 10.3389/fimmu.2022.946628. eCollection 2022.
8
Gut dysbiosis and small intestinal bacterial overgrowth as independent forms of gut microbiota disorders in cirrhosis.
World J Gastroenterol. 2022 Mar 14;28(10):1067-1077. doi: 10.3748/wjg.v28.i10.1067.
9
Altered Microbiome in Patients With Cirrhosis and Complications.
Clin Gastroenterol Hepatol. 2019 Jan;17(2):307-321. doi: 10.1016/j.cgh.2018.08.008. Epub 2018 Aug 9.
10
Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis.
J Hepatol. 2020 May;72(5):1003-1027. doi: 10.1016/j.jhep.2020.01.017. Epub 2020 Jan 28.
引用本文的文献
1
The Gut-Organ Axis within the Human Body: Gut Dysbiosis and the Role of Prebiotics.
Life (Basel). 2023 Oct 8;13(10):2023. doi: 10.3390/life13102023.
2
Alterations in the "Gut-Liver Axis" on Rats with Immunological Hepatic Fibrosis.
J Immunol Res. 2023 Sep 21;2023:5577850. doi: 10.1155/2023/5577850. eCollection 2023.
3
Future Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy.
Antibiotics (Basel). 2023 May 8;12(5):868. doi: 10.3390/antibiotics12050868.
4
Research Progress on the Therapeutic Effect of Polysaccharides on Non-Alcoholic Fatty Liver Disease through the Regulation of the Gut-Liver Axis.
Int J Mol Sci. 2022 Oct 3;23(19):11710. doi: 10.3390/ijms231911710.
5
Effects of Previous Kasai Surgery on Gut Microbiota and Bile Acid in Biliary Atresia With End-Stage Liver Disease.
Front Med (Lausanne). 2021 Sep 27;8:704328. doi: 10.3389/fmed.2021.704328. eCollection 2021.
本文引用的文献
1
Faecal cytokine profiling as a marker of intestinal inflammation in acutely decompensated cirrhosis.
JHEP Rep. 2020 Dec;2(6):100151. doi: 10.1016/j.jhepr.2020.100151. Epub 2020 Jul 30.
2
Antimicrobial resistance in chronic liver disease.
Hepatol Int. 2020 Jan;14(1):24-34. doi: 10.1007/s12072-019-10004-1. Epub 2019 Dec 3.
3
Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease.
Nature. 2019 Nov;575(7783):505-511. doi: 10.1038/s41586-019-1742-x. Epub 2019 Nov 13.
4
Drug-Resistant Bacteremia Transmitted by Fecal Microbiota Transplant.
N Engl J Med. 2019 Nov 21;381(21):2043-2050. doi: 10.1056/NEJMoa1910437. Epub 2019 Oct 30.
5
The gut-liver axis in liver disease: Pathophysiological basis for therapy.
J Hepatol. 2020 Mar;72(3):558-577. doi: 10.1016/j.jhep.2019.10.003. Epub 2019 Oct 14.
6
Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
J Hepatol. 2019 Dec;71(6):1216-1228. doi: 10.1016/j.jhep.2019.08.005. Epub 2019 Aug 13.
7
Causes and Consequences of Innate Immune Dysfunction in Cirrhosis.
Front Immunol. 2019 Feb 25;10:293. doi: 10.3389/fimmu.2019.00293. eCollection 2019.
8
Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent infection.
Gut. 2019 Oct;68(10):1791-1800. doi: 10.1136/gutjnl-2018-317842. Epub 2019 Feb 11.
9
PROFIT, a PROspective, randomised placebo controlled feasibility trial of Faecal mIcrobiota Transplantation in cirrhosis: study protocol for a single-blinded trial.
BMJ Open. 2019 Feb 15;9(2):e023518. doi: 10.1136/bmjopen-2018-023518.
10
Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide.
Gastroenterology. 2019 Apr;156(5):1368-1380.e10. doi: 10.1053/j.gastro.2018.12.005. Epub 2018 Dec 13.
Zotero 插件